LANXESS donates disinfectant to hospitals in Wuhan
- Donation of 1 ton of Rely+On Virkon high level disinfectant, can be diluted into 100,000 litres of solution
- Rely+On Virkon effective against coronavirus
The coronavirus continues to cause new fatalities every day in China. To help fight the epidemic, specialty chemicals company LANXESS has donated one ton of its highly effective Rely+On Virkon disinfectant to hospitals in Wuhan and two surrounding cities. The high level powder disinfectant is diluted with water and in this quantity is sufficient for 100,000 litres of disinfectant solution. The donation was already sent from the production plant in Sudbury, England, in the first week of February and arrived at the hospitals yesterday, February 16.
“LANXESS feels deeply connected to the people in China, not least because of our 1,200 employees and eight production sites in the country,” says Michael Schäfer, Head of LANXESS’s Material Protection Products business unit, where Rely+On Virkon is manufactured. “With our disinfectant Rely+On Virkon we can effectively help to contain the epidemic.”
Independent tests have proven that Rely+On Virkon inactivates a closely related surrogate of the currently spreading coronavirus strain. From these tests it can be concluded that Rely+On Virkon is also effective against SARS-CoV-2.
Rely+On Virkon is diluted for application and sprayed on hard surfaces and equipment. It can therefore help to reduce the risk of contamination of surfaces, door handles, tables or chairs during disinfection measures in hospitals, but also at public transport terminals, airports, shopping malls, etc.
“LANXESS feels deeply connected to the people in China, not least because of our 1,200 employees and eight production sites in the country,” says Michael Schäfer, Head of LANXESS’s Material Protection Products business unit, where Rely+On Virkon is manufactured. “With our disinfectant Rely+On Virkon we can effectively help to contain the epidemic.”
Rely+On Virkon inactivates coronavirus quickly
Independent tests have proven that Rely+On Virkon inactivates a closely related surrogate of the currently spreading coronavirus strain. From these tests it can be concluded that Rely+On Virkon is also effective against SARS-CoV-2.
Rely+On Virkon is diluted for application and sprayed on hard surfaces and equipment. It can therefore help to reduce the risk of contamination of surfaces, door handles, tables or chairs during disinfection measures in hospitals, but also at public transport terminals, airports, shopping malls, etc.
LANXESS is a leading specialty chemicals company with sales of EUR 6.7 billion in 2023. The company currently has about 12,400 employees in 32 countries. The core business of LANXESS is the development, manufacturing and marketing of chemical intermediates, additives and consumer protection products. LANXESS has achieved leading positions in the Dow Jones Sustainability Index and the MSCI ESG and ISS ESG ratings, among others, for its commitment to sustainability.
This company release contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors, nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.
